Clinical Trial Detail

NCT ID NCT02855125
Title A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Taiho Oncology, Inc.
Indications

lung non-small cell carcinoma

Therapies

Tegafur-gimeracil-oteracil Potassium

TAS-114 + Tegafur-gimeracil-oteracil Potassium

Age Groups: senior adult

No variant requirements are available.